Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer

Authors: Maddalena Barba, Patrizia Vici, Laura Pizzuti, Luigi Di Lauro, Domenico Sergi, Anna Di Benedetto, Cristiana Ercolani, Francesca Sperati, Irene Terrenato, Claudio Botti, Lucia Mentuccia, Laura Iezzi, Teresa Gamucci, Clara Natoli, Ilio Vitale, Marcella Mottolese, Ruggero De Maria, Marcello Maugeri-Saccà

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Body mass index (BMI) is largely investigated as a prognostic and predictive factor in triple-negative breast cancer (TNBC). Overweight and obesity are linked to a variety of pathways regulating tumor-promoting functions, including the DNA damage response (DDR). The DDR physiologically safeguards genome integrity but, in a neoplastic background, it is aberrantly engaged and protects cancer cells from chemotherapy. We herein verified the role of BMI on a previously assessed association between DDR biomarkers and pathological complete response (pCR) in TNBC patients treated with neoadjuvant chemotherapy (NACT).

Methods

In this retrospective analysis 54 TNBC patients treated with NACT were included. The relationship between DDR biomarkers, namely phosphorylated H2A Histone Family Member X (γ-H2AX) and phosphorylated checkpoint kinase 1 (pChk1), and pCR was reconsidered in light of BMI data. The Pearson’s Chi-squared test of independence (2-tailed) and the Fisher Exact test were employed to assess the relationship between clinical-molecular variables and pCR. Uni- and multivariate logistic regression models were used to identify variables impacting pCR. Internal validation was carried out.

Results

We observed a significant association between elevated levels of the two DDR biomarkers and pCR in patients with BMI < 25 (p = 0.009 and p = 0.022 for γ-H2AX and pChk1, respectively), but not in their heavier counterpart. Results regarding γ-H2AX were confirmed in uni- and multivariate models and, again, for leaner patients only (γ-H2AXhigh vs γ-H2AXlow: OR 10.83, 95% CI: 1.79–65.55, p = 0.009). The consistency of this finding was confirmed upon internal validation.

Conclusions

The predictive significance of γ-H2AX varies according to BMI status. Indeed, elevated levels of γ-H2AX seemed associated with lower pCR rate only in leaner patients, whereas differences in pCR rate according to γ-H2AX levels were not appreciable in heavier patients. Larger investigations are warranted concerning the potential role of BMI as effect modifier of the relationship between DDR-related biomarkers and clinical outcomes in TNBC.
Literature
1.
go back to reference James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer-what is the risk factor? Eur J Cancer. 2015;51:705–20.CrossRefPubMed James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer-what is the risk factor? Eur J Cancer. 2015;51:705–20.CrossRefPubMed
2.
go back to reference Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23 Suppl 6:vi7–12.CrossRefPubMed Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23 Suppl 6:vi7–12.CrossRefPubMed
3.
go back to reference Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319–24.CrossRefPubMedPubMedCentral Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319–24.CrossRefPubMedPubMedCentral
4.
go back to reference Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31.CrossRefPubMedPubMedCentral Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31.CrossRefPubMedPubMedCentral
5.
go back to reference Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–82.CrossRefPubMedPubMedCentral Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–82.CrossRefPubMedPubMedCentral
6.
go back to reference Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11:R18.CrossRefPubMedPubMedCentral Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11:R18.CrossRefPubMedPubMedCentral
7.
go back to reference Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307–14.CrossRefPubMed Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307–14.CrossRefPubMed
8.
go back to reference Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29:4373–80.CrossRefPubMedPubMedCentral Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29:4373–80.CrossRefPubMedPubMedCentral
9.
go back to reference Orecchioni S, Reggiani F, Talarico G, Bertolini F. Mechanisms of obesity in the development of breast cancer. Discov Med. 2015;20:121–8.PubMed Orecchioni S, Reggiani F, Talarico G, Bertolini F. Mechanisms of obesity in the development of breast cancer. Discov Med. 2015;20:121–8.PubMed
10.
go back to reference Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15:248–54.CrossRefPubMed Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15:248–54.CrossRefPubMed
11.
go back to reference Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15:501–13.CrossRefPubMedPubMedCentral Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15:501–13.CrossRefPubMedPubMedCentral
12.
go back to reference Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011;18:829–40.CrossRefPubMed Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011;18:829–40.CrossRefPubMed
13.
go back to reference Cerdá C, Sánchez C, Climent B, Vázquez A, Iradi A, El Amrani F, et al. Oxidative stress and DNA damage in obesity-related tumorigenesis. Adv Exp Med Biol. 2014;824:5–17.CrossRefPubMed Cerdá C, Sánchez C, Climent B, Vázquez A, Iradi A, El Amrani F, et al. Oxidative stress and DNA damage in obesity-related tumorigenesis. Adv Exp Med Biol. 2014;824:5–17.CrossRefPubMed
14.
15.
go back to reference Maugeri-Saccà M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev. 2013;39:525–33.CrossRefPubMed Maugeri-Saccà M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev. 2013;39:525–33.CrossRefPubMed
16.
go back to reference Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73–112.CrossRefPubMed Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73–112.CrossRefPubMed
17.
go back to reference Maugeri-Saccà M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther. 2012;11:1627–36.CrossRefPubMed Maugeri-Saccà M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther. 2012;11:1627–36.CrossRefPubMed
18.
go back to reference Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget. 2015. doi:10.18632/oncotarget.6001 [Epub ahead of print].PubMedPubMedCentral Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget. 2015. doi:10.​18632/​oncotarget.​6001 [Epub ahead of print].PubMedPubMedCentral
19.
go back to reference Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed
20.
go back to reference Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, et al. DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: an exploratory analysis. PLoS One. 2016;11:e0149872.CrossRefPubMedPubMedCentral Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, et al. DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: an exploratory analysis. PLoS One. 2016;11:e0149872.CrossRefPubMedPubMedCentral
21.
go back to reference Yu CH. Resampling methods: concepts, applications, and justification. Pract Assess Res Eval. 2003;8(19):1–16. Yu CH. Resampling methods: concepts, applications, and justification. Pract Assess Res Eval. 2003;8(19):1–16.
22.
go back to reference von Minckwitz G, Fontanella C. Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. J Natl Cancer Inst Monogr. 2015;2015(51):29–31.CrossRef von Minckwitz G, Fontanella C. Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. J Natl Cancer Inst Monogr. 2015;2015(51):29–31.CrossRef
23.
go back to reference Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19:6360–70.CrossRefPubMed Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19:6360–70.CrossRefPubMed
24.
go back to reference Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.CrossRefPubMed Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.CrossRefPubMed
25.
go back to reference Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101–10.CrossRefPubMedPubMedCentral Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101–10.CrossRefPubMedPubMedCentral
26.
go back to reference Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19:768–78.CrossRefPubMed Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19:768–78.CrossRefPubMed
27.
go back to reference Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014;146:189–97.CrossRefPubMed Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014;146:189–97.CrossRefPubMed
28.
go back to reference Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM. Overweight as a prognostic factor for triple-negative breast cancers in Chinese women. PLoS One. 2015;10:e0129741.CrossRefPubMedPubMedCentral Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM. Overweight as a prognostic factor for triple-negative breast cancers in Chinese women. PLoS One. 2015;10:e0129741.CrossRefPubMedPubMedCentral
29.
go back to reference Cakar B, Muslu U, Erdogan AP, Ozisik M, Ozisik H, Tunakan Dalgic C, et al. The role of body mass index in triple negative breast cancer. Oncol Res Treat. 2015;38:518–22.CrossRefPubMed Cakar B, Muslu U, Erdogan AP, Ozisik M, Ozisik H, Tunakan Dalgic C, et al. The role of body mass index in triple negative breast cancer. Oncol Res Treat. 2015;38:518–22.CrossRefPubMed
30.
go back to reference Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17:129.CrossRefPubMedPubMedCentral Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17:129.CrossRefPubMedPubMedCentral
31.
go back to reference Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150:127–39.CrossRefPubMed Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150:127–39.CrossRefPubMed
32.
go back to reference Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral
33.
go back to reference Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505–12.CrossRefPubMedPubMedCentral Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505–12.CrossRefPubMedPubMedCentral
34.
go back to reference Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, et al. Body mass index and treatment outcomes in metastatic breast cancer patients treated with eribulin. J Cell Physiol. 2015. doi:10.1002/jcp.25213 [Epub ahead of print]. Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, et al. Body mass index and treatment outcomes in metastatic breast cancer patients treated with eribulin. J Cell Physiol. 2015. doi:10.​1002/​jcp.​25213 [Epub ahead of print].
35.
go back to reference Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, et al. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. J Cell Physiol. 2015;230(8):1708–12.CrossRefPubMed Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, et al. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. J Cell Physiol. 2015;230(8):1708–12.CrossRefPubMed
36.
go back to reference Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget. 2014;5:10382–92.CrossRefPubMedPubMedCentral Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget. 2014;5:10382–92.CrossRefPubMedPubMedCentral
37.
go back to reference Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol. 2012;23:1838–45.CrossRefPubMed Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol. 2012;23:1838–45.CrossRefPubMed
38.
go back to reference Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683–8.PubMed Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683–8.PubMed
Metadata
Title
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
Authors
Maddalena Barba
Patrizia Vici
Laura Pizzuti
Luigi Di Lauro
Domenico Sergi
Anna Di Benedetto
Cristiana Ercolani
Francesca Sperati
Irene Terrenato
Claudio Botti
Lucia Mentuccia
Laura Iezzi
Teresa Gamucci
Clara Natoli
Ilio Vitale
Marcella Mottolese
Ruggero De Maria
Marcello Maugeri-Saccà
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-3045-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine